Previous 10 | Next 10 |
OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DecisionPoint Systems (NYSEMKT: DPSI ) stock is leading our top gainers. Target (NYSE: TGT ) stock is at the top of our losers list. Earnings reports are behind much of this morning’s stock movement....
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as...
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...
The shares of AIM ImmunoTech (NYSE:AIM) are rising the pre-market Thursday after the immuno-pharma company disclosed a summary of clinical data to back the synergistic effect of its cancer candidate Ampligen with checkpoint blockade therapies. A dsRNA drug, known as rintatolimod, Ampligen, is...
Capstone Green Energy (CGRN) +23% lands a service contract with one of the largest North American energy infrastructure companies. Mullen Automotive (MULN) +20% on conducting solid-state battery cell testing with BIC. AIM ImmunoTech (AIM) +13% provides summary of Ampligen ...
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen’s anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for the treatme...
Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...
- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct upcoming Phase 2 study ...
What to Know About Trading Penny Stocks on April 11th With another week of trading penny stocks getting off to an interesting start, there is a lot for investors to know. Considering that there is still an extremely high amount of volatility in the stock market, investors need to be on ...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...